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2Abstract
Objectives: We investigated long-term (to 25 years) seizure prognosis and survival in people
with newly diagnosed epilepsy in the community. We explored whether prognosis is different
in those with epilepsy (>2 unprovoked seizures) and those with a single seizure at
presentation.
Methods: This is a prospective observational cohort study of people with newly diagnosed
seizures. We investigated seizure outcome and survival in people presenting with a single
seizure and in those presenting with >2 seizures (epilepsy).
Results: 695 people (median follow-up 23.6 years) had unprovoked epileptic seizures. For
seizure analysis we excluded 38 people with missing data leaving 657 (309 male, and 249
aged <18 years). Seizures recurred in 67%. The 354 people with epilepsy were only slightly
more likely to have further seizure recurrence than the 302 people with a single seizure at
presentation (Hazard Ratio 1.32, 95% CI 1.09 to 1.59). In 327 people with complete follow-
up, 268 (82%, 95% CI 77 to 86) were in terminal remission; (80%, (95% CI 73 to 85) in
those with epilepsy at presentation). Premature mortality was increased both in people with
epilepsy (standardised mortality ratio 1.67; 95% CI 1.40 to 1.99) and those with a single
seizure at presentation (standardised mortality ratio 2.65; 95% CI 2.23 to 3.15). It is also high
in those with early remission.
Conclusion: People with epilepsy and with single seizures at presentation in the community
generally have good prognosis for seizure control with prolonged follow-up. The risk of
premature mortality is significantly increased in both groups.
Key words: epilepsy; seizure disorder, prognosis; mortality; single seizure.
3INTRODUCTION
Epilepsy remains the most common serious neurological disorder, yet there is little
information on long-term prognosis.[1] Few studies have examined prognosis in unselected
or community-based cohorts with more than ten years follow-up, and report terminal
remission in 44 to 70%.[2-5] The UK National General Practice Study of Epilepsy (NGPSE)
is a prospective cohort study of people with newly diagnosed seizures set up in 1984 to
determine the prognosis of people with new onset seizures.[6] The last reports on prognosis
were at nine years follow-up.[7;8] Long-term mortality to April 2009 has been reported.[9]
We now provide a comprehensive review of the outcome of those with epileptic seizures up
to 25 years after onset, including probability of seizure recurrence, remission, patterns of
seizure recurrence and mortality to see whether both seizure prognosis and survival are as
usually suggested.
METHODS
The methodology of the NGPSE has been previously described.[6] Between 1984 and 1987
UK General Practitioners (GPs) registered people with newly suspected seizures. Six months
after registration a diagnostic panel reviewed all 1195 registered using contemporaneous
data.[6] Those with a prior diagnosis of epilepsy (104 (9%)) or an alternative diagnosis (79
(7%)) were excluded. For the current analysis we excluded those with febrile seizures (220
(18%)).[10] The remaining 792 (66%) were classified as having definite (564 (47%)) or
probable epileptic seizures (228 (19%)). Subsequently those with epileptic seizures were
classified into four groups: idiopathic/cryptogenic seizures (1980s definition – no identified
predisposing cause); remote symptomatic seizures (CNS lesions acquired postnatally); acute
symptomatic seizures (occurring <3 months after an acute insult); associated with congenital
neurological deficits.[10] This classification was made using only information available six
months after the seizure prompting registration (the index seizure) and no changes were made
based on future outcomes. Follow-up of those with epileptic seizures used postal
questionnaires sent to all individuals’ GPs approximately yearly until 1997, with further
follow-up in 2001 and in 2009. For the current analysis, to enable comparison with other
cohorts, we excluded people with acute symptomatic seizures (97 (12%)), and analysed those
with epilepsy (recurrent unprovoked seizures at presentation) and those with a single
unprovoked seizure at presentation separately, as well as the whole group. We also separately
analysed those with idiopathic/cryptogenic seizures and the group of people with remote
4symptomatic seizures (in which we included those with congenital neurological deficits). As
sensitivity analyses, the main analyses were repeated in the whole group of people with
epileptic seizures, including those with acute symptomatic seizures, and in the subgroup with
definite unprovoked epileptic seizures.
A complete description of the methodology of the NGPSE is available in the supplementary
methods.
Patient involvement. This observational study was started in the 1980s and, although no
patients were involved in the design, recruitment or conduct, epilepsy support groups were
aware of it.
Statistics
The number of seizures prior to the index seizure was estimated and grouped. The date of the
first seizure after the index seizure was noted, as were the date of the first seizure occurring at
least five years, and at least ten years, after the index seizure. The date of the last follow-up at
which seizure status was recorded was taken as the end of follow-up for analyses of seizure
outcome; those with no seizure data were excluded from analysis of seizure outcome.
Kaplan-Meier analysis was used to investigate probability of seizure recurrence after the
index seizure, and after five and ten years after the index seizure. Factors affecting seizure
recurrence were determined using Cox regression, unless proportionality assumptions were
not met, when the log rank test was used. Competing risks regression with probability of
seizure recurrence as the outcome of interest and death as a competing interest was also
performed. For analysis of survival, the end of follow-up was death or 5th October 2009,
whichever occurred earlier.
For each 12-month period since the index seizure, a dichotomous variable was calculated
denoting the presence or absence of seizures during that 12-month period, with no distinction
between seizure types. Using these data, time to the completion of the first three-year and
five-year remissions from the index seizure were noted, as well as presence or absence of
terminal 5-year remission. Patterns of seizure remission and relapse were described, with
follow-up duration, using these dichotomous variables; the chi squared test was used to
compare those with a single seizure and those with epilepsy. The dichotomous variables were
used to construct a graph illustrating the probability of being seizure-free each year stratified
on seizure status in the preceding year.
5The Standardised Mortality Ratio (SMR) for the whole cohort with unprovoked seizures was
estimated as described previously.[9] Expected numbers of deaths were estimated using age,
sex and calendar year-specific death rates in England and Wales.[11] SMRs were also
estimated for people with early remission (those who became seizure-free by the second year
and subsequently remained seizure-free throughout follow-up), for people with a single
notified seizure ever and for those with more than one notified seizure ever. Median duration
from index seizure to death was estimated.
Data were analysed using Stata v13.1 (Texas). Confidence intervals (CIs) for binomial
proportions (Wilson method) and differences between proportions (Newcombe method) were
calculated using CIA software.[12]
Ethics approval. The National Research Ethics Committee approved the on-going follow-up
of the cohort in November 2007 (REC Reference 07/H0720/160), as did the National
Information Governance Board Ethics and Confidentiality Committee (PIAF 1-05(g)/2008
NGPSE) granting Section 251 support.
Role of the funding source:
The funders had no role in the design and conduct of the study or in the decision to publish.
Prof Sander had full access to all the data in the study and had final responsibility for the
decision to submit for publication.
RESULTS
Demographics
The study profile for the NGPSE is shown in the supplementary figure. For the whole cohort
of 695 people with unprovoked epileptic seizures, the median duration of follow-up (to death
or last follow-up) from the index seizure was 16.6 years (interquartile range [IQR] 10.2,
24.0); 255 people (37%) died by 5th October 2009. For those alive (n=440) on this date,
median duration of follow-up was 23.6 years (IQR 22.2, 24.7).
At the time of GP registration with the study, 370/695 (53%) people had had more than one
seizure (“epilepsy” group) and 324 (47%) people had had a single seizure (“single seizure”
group) (table 1); one person was excluded from analyses as we could not determine whether
the index seizure was the first.
6Table 1. Study characteristics
Single seizure
group
Epilepsy
group
Whole cohort
Initial cohort 402 389 792a
Acute symptomatic seizures 78 19 97
N after excluding people with
acute symptomatic seizures
324 370 695
Mortality analyses
Mean dDuration to death in
years; median, (IQR)
3.7 (1.3, 12.9) 9.0 (3.6, 15.8) 6.5 (2.0, 14.9)
Missing seizure data 22 16 38
N after excluding people with
missing seizure data
302 354 657a
Seizure outcome cohort
Sex male (%) 140 (46%) 169 (48%) 309 (47%)
Age at index seizure in years;
median (IQR)
27.0 (12.7,
58.01)
23.5 (13.9,
55.6)
24.9 (13.67,
56.9)
Age <18 years at index seizure 118 (39%) 131 (37%) 249 (38%)
Died during follow-up period
(%)
109 (36%) 113 (32%) 223 (34%)
Years of follow up; median
(IQR)
17.0 (10.0,
24.1)
22.3 (12.1,
24.1)
17.3 (11.1,
24.1)
Years of follow-up in those
alive at study end; median
(IQR)
23.7 (22.4,
24.7)
23.6 (17.2,
24.7)
23.6 (22.2,
24.7)
Presumed aetiology
Idiopathic/cryptogenic 230 (76%) 283 (80%) 513 (78%)
Symptomatic 72 (24%) 71 (20%) 144 (22%)
Legend. IQR; interquartile range
a in one person it was not possible to ascertain whether the index seizure was the first
7Ten individuals had >5 years with missing seizure data but with further follow-up, while 28
people had no seizure follow-up at all; each of these 28 died during the follow-up period, 22
(79%) within six months of the index seizure. These 38 people were excluded from the
analyses of seizure outcome which are based on the remaining 657 individuals. Three
quarters (513 people, 78%) were classified as having idiopathic/cryptogenic seizures and 144
(22%) had remote symptomatic seizures (including those due to congenital neurological
deficits).
Probability of seizure recurrence after the index seizure
Seizures recurred in 258/354 (73%, 95% CI 68 to 77) in those with epilepsy at presentation
and in 184/302 (61%, 95% CI 55 to 66) of those with a single seizure. Those with epilepsy
were only slightly more likely to have further seizure recurrence than those with a single
seizure (hazard ratio [HR] 1.32, 95% CI 1.09 to 1.59). Those with greater numbers of
seizures before the index seizure were increasingly likely to have further seizure recurrence
(compared with those with a single seizure at presentation, HR 1.21, 95% CI 0.99 to 1.48 for
those with 1-5 seizures before the index seizure, HR 1.41, 95% CI 0.99 to 2.01 for 6-10
seizures before the index seizure and HR 2.72, 95% CI 1.84 to 4.03 for >10 seizures before
the index seizure). Neither sex (HR 0.99, 95% CI 0.82 to 1.19) nor age at index seizure (HR
1.00, 95 % CI 0.996 to 1.00) affected probability of seizure recurrence. Those with onset at
18 years or older were less likely to have seizure recurrence; the difference was not
significant using standard analyses (HR 0.83, 95% CI 0.69, 1.01), but was when competing
risks analysis was used (Subhazard ratio 0.79, 95% CI 0.66, 0.96). Table 2 shows the
probability of continued seizure-freedom at various time points in the whole cohort, in those
with epilepsy and those with a single seizure at presentation, and in those with a single
seizure by five and ten years after presentation.
8Table 2. Probability of remaining seizure-free after various periods from the index seizure, in the whole group, and in groups stratified
by seizure occurrence.
Outcome Whole group
(n=657)
(95% CI)
Single seizure at
presentation
(N=302)
(95% CI)
Epilepsy at
presentation
(N=354)
(95% CI)
Single seizure by
5 years (N=113)
(95% CI)
Single seizure by
10 years (N=94)
(95% CI)
Seizure-free at 5 years
from the index seizure
0.37 (95% CI
0.33 to 0.41)
0.43 (95% CI
0.37 to 0.49)
0.32 (95% CI
0.27 to 0.37)
Seizure-free at 10 years
from the index seizure
0.33 (95% CI
0.29 to 0.37)
0.39 (95% CI
0.33 to 0.44)
0.29 (95% CI
0.24 to 0.33)
0.90 (95% CI
0.82 to 0.94)
Seizure-free at 15 years
from the index seizure
0.32 (95% CI
0.28 to 0.35)
0.38 (95% CI
0.33 to 0.44)
0.26 (95% CI
0.22 to 0.31)
0.89 (95% CI
0.81 to 0.93)
0.99 (95% CI
0.92 to 0.998)
Seizure-free at 20 years
from the index seizure
0.31 (95% CI
0.28 to 0.35)
0.38 (95% CI
0.33 to 0.44)
0.26 (95% CI
0.21 to 0.31)
0.89 (95% CI
0.81 to 0.93)
0.99 (95% CI
0.92 to 0.998)
Seizure-free at 25 years
from the index seizure
0.29 (95% CI
0.26 to 0.33)
0.36 (95% CI
0.30 to 0.42)
0.24 (95% CI
0.20 to 0.29)
0.83 (95% CI
0.72 to 0.90)
0.92 (95% CI
0.80 to 0.97)
Legend. CI; confidence interval
Remission
Details of remission are shown in table 3.
9Table 3. Probability of having experienced a three-year remission and five year remission by 5, 10 and 15 years after the index seizure,
and five year terminal remission
Epilepsy at presentation Single seizure at presentation
3-year remission (HR for those with epilepsy 0.83 (95% CI
0.70, 0.99)
N=329 with follow-up to 3 years N=260 with follow-up to 3 years
Probability of remission by 3 years from the index seizure 0.38 (95% CI 0.33 to 0.44) 0.48 (95% CI 0.43 to 0.55)
Probability of remission by 5 years from the index seizure 0.67 (95% CI 0.62 to 0.72) 0.73 (95% CI 0.67 to 0.78)
Probability of remission by 10 years from the index seizure 0.84 (95% CI 0.80 to 0.88) 0.91 (95% CI 0.86 to 0.94)
Probability of remission at 15 years from the index seizure 0.89 (95% CI 0.85 to 0.92) 0.94 (95% CI 0.90 to 0.97)
5-year remission (HR for those with epilepsy 0.79 (95% CI
0.66 to 0.95)
N=318 with follow-up to 5 years N=249 with follow-up to 5 years
Probability of remission by 5 years from the index seizure 0.32 (95% CI 0.27 to 0.38) 0.45 (95% CI 0.39 to 0.52)
Probability of remission by 10 years from the index seizure 0.72 (95% CI 0.67 to 0.77) 0.82 (95% CI 0.77 to 0.86)
Probability of remission by 15 years from the index seizure 0.81 (95% CI 0.76 to 0.85) 0.89 (95% CI 0.84 to 0.93)
5-year terminal remission N=318 with follow-up to 5 years N=249 with follow-up to 5 years
Number (%) in 5-year terminal remission at end of FU
(difference 7%, 95% CI -0.3 to 14)
231 (73%, 95% CI 67 to 77) 198 (80%, 95% CI 74 to 84)
Number (%) in 5-year terminal remission in those followed to
2009 (difference 5%, 95% CI -4 to 13)
142/178 (80%, 95% CI 73 to 85) 126/149 (85%, 95% CI 78 to 89)
5-year terminal remission, off AEDs in those followed to
2009 (difference 8%, 95% CI -3 to 18)
103/142 (73%, 95% CI 65 to 79) 101/126 (80%, 95% CI 72 to 86)
Legend. CI; confidence interval.
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In 327 people with follow-up to 2009, 268 (82%, 95% CI 77 to 86) were in terminal
remission (i.e. no seizures for the last five years of follow-up); 204 (76%, 95% CI 71, 81) of
those were off anti-epileptic drugs (AEDs), while six people (all with epilepsy at
presentation) were not in remission but not taking AEDs. There was no difference in the
percentage in 5-year terminal remission between adults and children.
Outcome after 5-years
The 568 people with >5 years of follow-up were divided into four seizure pattern groups
depending on seizures prior to the index seizure and during the first five years of follow-up;
three people had missing data. Of the others, 113 (20%) had no seizures before the index
seizure or during the first five years of follow-up, 136 (24%) had no seizures before the index
seizure, but had seizures during the first five years, 102 (18%) had seizures before the index
seizure but not since, and 214 (38%) had seizures before and after the index seizure. The log
rank test indicated a significant difference in probability of later seizure recurrence among the
groups (p < 0.0001) (figure 1).
Seizure Patterns
Patterns of seizure remission and relapse are illustrated in table 4. There was no significant
difference in the distribution of pattern groups between those with epilepsy and those with a
single seizure at presentation (p = 0.084).
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Table 4: Patterns of seizure remission and relapse after the index seizure, based on dichotomous seizure variables
Pattern N (%) Years of follow-up
(Median, IQR)
N (%) Years of follow-up
(Median, IQR)
Epilepsy at presentation (N=354) Single seizure at presentation
(N=302)
Always seizure-free apart from index seizure 96 (27%) 22.5 (12, 24) 118 (39%) 15.9 (11, 24)
No year of seizure-freedom 30 (8%) 7.0 (1, 23) 28 (9%) 1.0 (0.7, 2)
Initial seizure free year(s) followed by seizures 6 (2%) 13.0 (6, 25) 6 (2%) 17.9 (12, 24)
Initial year(s) with seizures, followed by seizure-freedom 79 (22%) 22.5 (12, 24) 54 (18%) 22.9 (13, 24)
Initially & finally seizure-free year(s), but with one period
(at least one year with seizures) of seizures intervening
32 (9%) 16.8 (14, 24) 22 (7%) 22.5 (15, 24)
Initially and finally year(s) with seizures, but with one
period (at least one year) of seizure-freedom intervening
13 (4%) 12.0 (6, 23) 7 (2%) 15.9 (4, 24)
Complex pattern, but with terminal seizure-freedom of at
least one year
68 (19%) 22.7 (14, 24) 45 (15%) 23.2 (12, 25)
Complex pattern with seizures at the end of follow-up 30 (8%) 24.1 (14, 25) 22 (7%) 23.9 (15, 25)
Legend: IQR; interquartile range
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In those with no missing data, 49% (298/606) were seizure-free during the first year of
follow-up. This increased to 74% by the second year, and was consistently over 80% by the
sixth year of follow-up, although it was not always the same people who remained seizure-
free. The proportion who were seizure-free one year and relapsed the following year was
small (always <11%) but was never zero. Figure 2 shows the probability of being seizure-free
in any year stratified on seizure status in the previous year.
Seizure outcome, stratified on seizure status in the previous five years at five and at ten years
is illustrated in figure 3.
Mortality
In the whole cohort (695 people) 255 died by October 2009 (SMR 2.07, 95% CI 1.83 to
2.34). The SMR was 2.65 (95% CI 2.23 to 3.15) in those with a single seizure and 1.67 (95%
CI 1.40 to 1.99) in those with epilepsy at presentation. The SMR was higher in those with the
index seizure in childhood (<18 years; SMR 5.34, 95% CI 3.32, 8.59) than in those with
onset later (SMR 1.98, 95% CI 1.75, 2.25), although only 17 with childhood onset died (3.2
expected). Most (13/17) died as adults.
In those with a single seizure at presentation and with at least two years of follow-up, 146
people had early remission (no reported seizures beyond the first year of follow-up; SMR
1.86; 95% CI 1.40 to 2.46). In those with epilepsy at presentation, 145 people had early
remission (SMR 1.44; 95% CI 1.06 to 1.95). The SMR in 112 people with a single notified
seizure ever and with >1 year follow-up was 1.57 (95% CI 1.15 to 2.13) (1.62 in males and
1.53 in females). Most (91/112; 81%, 95% CI 73 to 87) had at >10 years of follow-up. The
SMR in 558 people with more than one notified seizure (before or after the index seizure)
was 1.99 (95% CI 1.73 to 2.30).
Presumed aetiology
The main analyses were repeated for those with idiopathic/cryptogenic seizures (N=513) and
those with remote symptomatic seizures (N=144) (table 5). Overall the group with
symptomatic epilepsy fared worse, with bigger differences for 5-year terminal remission and
mortality.
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Table 5. Seizure recurrence, remission, and mortality in people with cryptogenic/idiopathic seizures and those with symptomatic
seizures.
Cryptogenic/idiopathic seizures Remote symptomatic seizures
N 513 144
Single seizure at presentation 230 (45%) 72 (50%)
Seizure recurrence 336 (65%) 107 (74%)
Probability of remaining seizure free at 10 years* 0.36 (95% CI 0.32 to 0.40) 0.23 (95% CI 0.16 to 0.31)
3 year remission N=488 with follow-up to 3 years N=102 with follow-up to 3 years
Probability of remission by 5 years* 0.72 (95% CI 0.68 to 0.76) 0.58 (95% CI 0.49 to 0.68)
Probability of remission by 10 years* 0.89 (95% CI 0.86 to 0.91) 0.75 (95% CI 0.66 to 0.84)
Probability of remission by 15 years* 0.92 (95% CI 0.89 to 0.94) 0.87 (95% CI 0.77 to 0.94)
5 year remission N=477 with follow-up to 5 years N=91 with follow-up to 5 years
Probability of remission by 5 years* 0.40 (95% CI 0.36 to 0.45) 0.26 (95% CI 0.19 to 0.37)
Probability of remission by 10 years* 0.78 (95% CI 0.74 to 0.82) 0.65 (95% CI 0.55 to 0.76)
Probability of remission by 15 years* 0.86 (95% CI 0.82 to 0.89) 0.75 (95% CI 0.64 to 0.84)
5-year terminal remission
Number (%) in 5-year terminal remission at end of FU 377/477 (79%; 95% CI 75 to 82) 52/91 (57%; 95% CI 47 to 67)
Mortality
SMR whole cohort 1.50 (95% CI 1.26 to 1.78) 3.25 (95% CI 2.74 to 3.86)
SMR (single seizure at presentation) 1.89 (95% CI 1.47 to 2.43) 4.13 (95% CI 3.26 to 5.23)
SMR (epilepsy at presentation) 1.25 (95% CI 0.97 to 1.60) 2.59 (95% CI 2.01 to 3.32)
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SMR (single notified seizure) 1.49 (95% CI 1.02 to 2.19) 1.72 (95% CI 1.03 to 2.85)
*after the index seizure
Legend: CI; confidence interval. SMR; standardised mortality ratio. FU; follow-up
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Sensitivity analyses
The supplementary table shows the results of two sensitivity analyses. We found no evidence
of difference between the current cohort and the original cohort (including people with acute
symptomatic seizures), with overlapping confidence intervals throughout. Comparison of the
current cohort with only those with definite unprovoked epileptic seizures showed largely
similar results but those with definite epilepsy were slightly more likely to have recurrent
seizures and slightly less likely to have early 5-year remission.
DISCUSSION
The NGPSE is a pragmatic, observational study set up in the 1980s, following an unselected
cohort of people of all ages with newly diagnosed seizures of any type, to establish the long-
term prognosis. For this analysis we excluded people with acute symptomatic seizures, and
have separately investigated those with a single seizure and those with epilepsy at
presentation. Two-thirds of people had >1 seizure recurrence after the index seizure; this was
slightly more likely in people with epilepsy at presentation. We found high rates of seizure
remission with slightly higher rates in those with a single seizure at presentation. Overall
almost one third remained seizure-free after the index seizure while another one fifth entered
terminal remission after initial seizures (table 4). The probability of becoming seizure-free
becomes more remote the longer seizures persist. The proportion of people who become
seizure-free and then subsequently relapse is small (probability of relapse in the subsequent
10 years was 0.14 in those seizure-free in the first five years and 0.08 in those seizure-free in
the second five years). In 327 people with follow-up to 2009, 268 (82%, 95% CI 77 to 86)
were in terminal remission, and 204 (62% of those with follow-up) were also off AEDs.
Premature mortality is, however, higher than in the general population in all subgroups
including those with a single reported seizure.
This study’s strengths include long-term prospective follow-up of an unselected population-
based cohort. Its weaknesses are inherent to its design. During a long-term, observational
study it is inevitable that some people are lost to follow-up, either briefly or until the study
end. Survival analysis assumes that any right censoring (loss to follow-up) is independent of
survival, but those who were not followed-up may be in some way different. Our information
came via GPs, and during this long study some GPs changed; the new GPs may not be as
interested in epilepsy or the study. Some individuals may not have notified their GP of all
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seizures, or they may not have been recorded in the medical records; this applies to all seizure
studies without direct observation. Doubtless with newer imaging techniques, many in the
idiopathic/cryptogenic groups would be reclassified as having lesions; nevertheless, it is not
possible to have 25 year follow-up in 2015 on people investigated using modern techniques.
It is possible that use of the ‘operational’ clinical definition of epilepsy would reclassify some
currently classified as having single seizures as having epilepsy.[13] As we demonstrated
showed little prognostic difference between those with epilepsy and those with a single
seizure, it is unclear how this would have affected our results. GPs continued with their usual
practice; the study team had no influence over did not guide medical care or any
investigations performed.
The number of seizures prior to the index seizure was predictive of the probability of seizure
recurrence after the index seizure, but the presence of seizures in the first five years after the
index seizure seems more important in seizure prognosis. In the same cohort, it was
previously shown that the number of seizures during the first six months after presentation
was the most important predictor of remission.[8]
Apart from the NGPSE, there are only two other population-based studies with a longitudinal
cohort larger than 250 subjects, only one of which one has follow-up for >10 years.[2;14;15]
The percentages of people in terminal remission in previously reported studies range between
about 44 and 70.[2-5;16] Earlier analysis of the NGPSE, also excluding people with acute
symptomatic seizures and excluding those with a single seizure at presentation found that
60% (95% CI 52 to 68) had had a 5-year remission (not necessarily terminal remission) by
nine years.[17] We found higher figures (80% in 5-year terminal remission in people with
epilepsy at presentation followed to 2009). This may be influenced by the long follow-up in
this study, with the proportion seizure-free each year consistently greater than 80% after six
years. This finding of higher proportions in terminal remission associated with longer follow-
up was previously suggested in two smaller cohort studies.[2;18] The high proportion with
terminal remission seen in the NGPSE is not entirely explained by the inclusion of people
with single seizures at presentation (Table 3); 73% of those with more than one seizure at
presentation were in terminal remission by the end of follow-up (80% in those with complete
follow-up). This higher rate of seizure remission may also be related to the community-based
nature of the cohort, and may approximate to the ‘true’ population rate.
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It is well recognised, through prospective cohort studies, that people with epilepsy are at
increased risk of premature mortality, with this risk present at seizure onset and subsequently
decreasing (but persisting) over time,; with this risk variesying with underlying aetiology.
[19] In the NGPSE cohort we have We previously demonstrated showed in this cohort that
the risk of premature mortality is increased throughout prolonged follow-up.[9] We have now
shown that the SMR is significantly raised in people with early remission and in people with
only a single notified unprovoked seizure. The SMR was increased in each group, including
in those with idiopathic/cryptogenic seizures. Thus, prognosis for survival is not good, even
amongst those whose seizures have ceased; the reasons for this are unknown. An early study
from the US found the SMR to be 2.3 in 159 people with a single seizure.[14] In other studies
reporting survival after an isolated seizure, it is unclear how many remained seizure-
free.[20;21]
The reasons for higher mortality in those presenting with a single seizure than those with
epilepsy are unknown, and indeed the finding seems counterintuitive. More people in the
single seizure group had symptomatic aetiology (24%) than the epilepsy group (20%), and
people in the single seizure group died earlier (table 1). Whilst the overall disparity in
mortality rates between the two groups may be partially explained by the higher proportion
with symptomatic aetiology in the single seizure group, it does not explain why those with
symptomatic aetiology in those with single seizures at presentation have a higher SMR (4.1)
than those with symptomatic aetiology in those with epilepsy at presentation (SMR 2.6)
(table 5). People with an idiopathic/cryptogenic aetiology in those with single seizures at
presentation had a similarly higher SMR (1.9) than those with epilepsy at presentation (SMR
1.2) although the disparity is less marked. It is possible that some people originally classified
as having a single unprovoked seizure had, in fact, had a provoked seizure which was not
recognised. The cause of the provoked seizure may have been lifestyle habits (such as alcohol
abuse, or alcohol or drug withdrawal) [22] which could contribute to premature mortality.
Alternatively, presenting after a single seizure might be a surrogate for seizure severity. The
higher mortality rate in those with single seizures could, conversely, influence the probability
of seizure recurrence as those who have died are not at risk of a further seizure. Using
competing risks analysis for the main analyses (data not shown), however, found the
differences between those with a single seizure and those with epilepsy at presentation
marginally increased, but CIs overlapped throughout.
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People with epilepsy have a higher rate of a variety of comorbidities than the general
population.[23] Some of these comorbidities may be a determinant of premature
mortality.[24] Our results suggest that these co-morbidities may indeed constitute a major
factor in premature mortality, particularly in people in long-term remission. This needs
thorough investigation to allow for preventative strategies.
One of the key features of the current analysis was the dichotomisation of the original cohort
into people with a single unprovoked seizure and people with epilepsy at the time of
presentation to the study. This allowed for accurate depiction of the long-term seizure and
mortality prognosis of people presenting with a single unprovoked seizure, which few studies
have addressed.[25] We can now say that the probability of remaining seizure free after 5
years is 37 to 49% in those presenting with a single unprovoked seizure,; this is similar to 48
to 58% found in the MESS study [26] and to the 40 to 47% of people who entered 5-year
remission rates not dissimilar with 3 months of a first seizureto those seen in the FIRST[26]
study. [27]and MESS[27] studies . More encouragingly the prognosis is far better in those
who still have only had a single seizure at 5 and 10 years with only 17% and 8% probability
of having a further seizure by the end of follow-up. This is of great prognostic value for
clinicians counselling anxious people presenting with a single unprovoked seizure.
We have also shown that seizure prognosis in those with a single seizure at presentation is
significantly, but only marginally, better than for those with >1 seizure at presentation. This
fact has previously been commented on by several authors (for example Berg (2008) [28])
but as described above, this picture is less clear when analysing mortality outcomes. By 25
years of follow-up the probability of having had no further seizures was only 0.36 in those
with a single seizure, compared with 0.29 in those with epilepsy at presentation.
We excluded people with acute symptomatic seizures in the main analyses to make the results
more comparable with other studies. Nevertheless, the results are similar when people with
acute symptomatic seizures are included.
The NGPSE is probably one of the last large cohort studies of people with epilepsy where
inclusion is determined by the presenting symptom. The perception of epilepsy as a
homogeneous entity is being replaced by the concept of it being a collection of genetic and
acquired conditions with a propensity to have unprovoked seizures. Consequently future
cohort studies in people with epilepsy are likely to be smaller, determined by aetiology (for
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example a genetic variant), which will allow for greater prognostic accuracy (in terms of both
seizure control and survival) of people with the individual epileptic syndromes.
Data sharing: No consent for data sharing with other parties was obtained, but the
corresponding author may be contacted to request a limited amount of anonymised data.
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FIGURES
Figure 1. Probability of seizure recurrence after the first five years of follow-up
Legend: sz; seizure
5y; 5 years
The log rank test indicated a significant difference in probability of later seizure recurrence
among the groups (p < 0.0001). There was a higher probability of recurrence in the two groups
with seizures in the first five years than in the two groups with no seizures then (p < 0.0001)
There were no differences between the two groups without seizures in the first five years (p =
0.30), or between the two groups with seizures (p = 0.17).
By 20 years after the index seizure, the probability of remaining seizure-free was:
0.89 (95% CI 0.81 to 0.93) in those with a single seizure at five years
0.81 (95% CI 0.71 to 0.88) in those with seizures only before the index seizure
0.53 (95% CI 0.44 to 0.62) for those with seizures only in the first five years
0.47 (95% CI 0.40 to 0.54) in those with seizures during both time periods.
Figure 2. Probability of seizure-freedom each year based on presence or absence of seizures in
the previous year (N=568 with follow-up of at least two years)
Figure 3. Seizure recurrence after five and ten years stratified by seizure status in the previous
five years
ONLINE SUPPLEMENT:
1. Complete study methodology
2. Supplementary figure. Study profile, showing those available for follow-up in 2009 and
those with follow-up achieved
3. Supplementary table. Sensitivity analysis. Comparing key outcomes in three cohorts:
the cohort in the current analysis (excluding people with acute symptomatic seizures,
single seizure and epilepsy at presentation combined); the whole cohort with definite or
possible epilepsy; those with definite epilepsy excluding those with acute symptomatic
seizures. For seizure outcomes we excluded people with no follow-up and those with
more than five years of missing data but with further follow-up).
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